Drugs.com - Clinical Trials

Kiadis Pharma Announces Positive Clinical Results for ATIR in Mismatched Bone Marrow Transplantations - Kiadis Pharma Proceeds with Pivotal Trial ATIR

Thu, 04 Dec 2008 19:30:59 GMT

Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™ AMSTERDAM--Dec. 4, 2008--CNW/ - Biopharmaceutical company Kiadis Pharma announces...

Results From the First and Largest Collaborative Study Confirm Role of Enbrel in Psoriatic Arthritis

Thu, 04 Dec 2008 19:30:32 GMT

- New data add to the body of evidence that show that Enbrel (etanercept) clears skin and can sustain this efficacy over time - Wyeth Europa, MAIDENHEAD, England, Dec.4, 2008: New data presented today at the ‘Gene to Clinic’ meeting taking...

Archemix Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology (ASH) Annual Meeting, December 6-9, 2008

Thu, 04 Dec 2008 19:00:24 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 4, 2008 - Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, today announced that data from the company's Phase 2a clinical trial of ARC1779...

Novelos Therapeutics and Academic Collaborators Present Posters at 2008 AACR Tumor Immunology Conference

Thu, 04 Dec 2008 18:50:37 GMT

Presentations Highlight Immunomodulatory Effects of NOV-002 in Animal Models NEWTON, Mass.--(BUSINESS WIRE)--Dec 4, 2008 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat...

Inovio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference

Thu, 04 Dec 2008 17:45:14 GMT

SAN DIEGO--(BUSINESS WIRE)--Dec 4, 2008 - Inovio Biomedical Corporation (NYSE Alternext: INO) and VGX Pharmaceuticals announced today they will make multiple presentations concerning electroporation-delivered DNA vaccines in the fight against...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

Thu, 04 Dec 2008 16:35:40 GMT

NEW HAVEN, Conn., December 04, 2008 /PRNewswire-FirstCall/ -- today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from December 6-9,...

Starpharma Holdings Limited SPL7013 Shows Activity Against All Major Clinically Relevant Human Papillomavirus (HPV) Strains

Thu, 04 Dec 2008 16:25:24 GMT

Melbourne, Dec 4, 2008 (ABN Newswire) - Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced new data showing that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits all four strains of the human papillomavirus...

MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes

Thu, 04 Dec 2008 14:30:02 GMT

Pivotal efficacy and safety studies meet primary endpoints VALENCIA, Calif., Dec. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that it has met the primary endpoints of its final two pivotal Phase 3 studies of...

EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting

Thu, 04 Dec 2008 14:05:36 GMT

Phase III data demonstrates significantly improved leukemia-free survival (LFS) for patients in complete remission Improved LFS correlates with improved overall survival TARRYTOWN, N.Y.--(BUSINESS WIRE)--Dec 4,...

Zevalin Data to be Presented at ASH 2008

Thu, 04 Dec 2008 14:00:09 GMT

12 presentations and posters on ZEVALIN(R) in Non-Hodgkin's Lymphoma scheduled SEATTLE, December 04, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced presentations or posters of interest related to Zevalin(R) (ibritumomab...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

Thu, 04 Dec 2008 13:55:15 GMT

EAST HANOVER, N.J., December 04, 2008 /PRNewswire/ -- More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses,...

Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting

Thu, 04 Dec 2008 13:45:22 GMT

Multiple Studies of Stapled Peptides, a new Drug Modality, Slated for Presentation at American Society of Hematology 2008 Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 4, 2008 - Aileron Therapeutics announced today that investigators from Aileron...

Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference

Thu, 04 Dec 2008 13:45:16 GMT

SAN DIEGO--(BUSINESS WIRE)--Dec 4, 2008 - Ambit Biosciences today announced that data for the company's lead compound, AC220, will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), occurring December 6 through 9,...

EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting

Thu, 04 Dec 2008 13:40:06 GMT

Phase III data demonstrates significantly improved leukemia-free survival (LFS) for patients in complete remission Improved LFS correlates with improved overall survival Regulatory News: TARRYTOWN, N.Y., Dec 04, 2008 (BUSINESS WIRE) --EpiCept...

Data Demonstrating Significant Efficacy of Viread in Treating Chronic Hepatitis B Published in New England Journal of Medicine

Thu, 04 Dec 2008 13:00:30 GMT

-- Important Findings for Treatment of One of World's Most Common Life-Threatening Liver Diseases -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec 3, 2008 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced the publication of detailed 48-week data...

ConjuChem's PC-DAC:Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials

Thu, 04 Dec 2008 12:20:09 GMT

- Product Extremely Well Tolerated - MONTREAL, December 03, 2008 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies, Inc. announced preliminary results today showing that its Type 2 diabetes product, PC-DAC(TM):Exendin-4, achieved statistically...

Surprising Results on Smoking Research Hispanic Versus White Female Smokers

Wed, 03 Dec 2008 20:50:15 GMT

ALBUQUERQUE, N.M., December 03, 2008 /PRNewswire/ -- The nation's first scientific study on the relationship between smoking and respiratory disease among Hispanic versus non-Hispanic white (NHW) women revealed that NHW women smokers were at greater...

Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement

Wed, 03 Dec 2008 20:00:34 GMT

HASBROUCK HEIGHTS, N.J.,Dec. 3, 2008--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today positive new data from a recently completed clinical trial of NX-1207, the Company’s investigational drug for BPH. The trial data shows that...

Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting

Wed, 03 Dec 2008 15:30:01 GMT

DALLAS--(BUSINESS WIRE)--Dec 3, 2008 - Memgen today announced that two of its clinical trials were selected for poster presentations at the annual meeting of the American Society of Hematology (ASH) on December 6-9. Both presentations highlight...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

Wed, 03 Dec 2008 15:10:25 GMT

CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting

Wed, 03 Dec 2008 15:05:36 GMT

BETHESDA, Md., December 03, 2008 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference...

Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting

Wed, 03 Dec 2008 15:05:05 GMT

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 3, 2008 - Sepracor Inc. (Nasdaq: SEPR) today announced that clinical study data for eslicarbazepine acetate in the treatment of epilepsy will be presented at the 62nd annual meeting of the American Epilepsy...

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH

Wed, 03 Dec 2008 14:45:06 GMT

SOUTH SAN FRANCISCO, Calif., December 03, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at...

Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

Wed, 03 Dec 2008 14:45:05 GMT

SOUTH SAN FRANCISCO, Calif., December 03, 2008 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...

Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology

Wed, 03 Dec 2008 14:41:01 GMT

Clinical Results Demonstrate Novel Mechanism Increases Bone Mineral Density and Increases Levels of Hemoglobin and Hematocrit CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 3, 2008 - Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a...

Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows

Wed, 03 Dec 2008 13:55:45 GMT

NEW YORK--(BUSINESS WIRE)--Dec 3, 2008 - Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of experiencing a cardiovascular...

Generex Announces Positive Results of Metformin Chewing Gum Trial

Wed, 03 Dec 2008 13:45:11 GMT

Results suggest that the Company's Metformin chewing gum is therapeutically equivalent to traditional Metformin tablets WORCESTER, MA, December 2, 2008 (GlobeNewswire) - Generex Biotechnology Corporation, the leader in drug delivery for metabolic...

POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials

Wed, 03 Dec 2008 13:35:34 GMT

PN 400 Demonstrated Statistically Significant Fewer Gastric Ulcers vs. Enteric Coated Naproxen CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec 3, 2008 - POZEN Inc. (NASDAQ: POZN), today announced positive Phase 3 trial results for its PN 400 product...

PN 400 Phase III Studies Show Clinically Meaningful Benefit in Reducing Gastric Ulcers Compared to Enteric-Coated Naproxen

Wed, 03 Dec 2008 13:25:10 GMT

LONDON, Dec. 3, 2008-AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric-coated naproxen 500 mg and...

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

Wed, 03 Dec 2008 13:20:25 GMT

First-line trial currently shows median overall survival of 27.5 months for OGX-011 in combination with docetaxel and prednisone and a 16.9 months overall survival for docetaxel and prednisone alone. Achievement...

SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition

Tue, 02 Dec 2008 19:40:47 GMT

DUBLIN, Calif., December 02, 2008 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th...

GENFIT Therapeutic Potential of GFT505 is Demonstrated in the Treatment of Cardiovascular Risk Associated With Pre-Diabetes

Tue, 02 Dec 2008 15:40:32 GMT

Efficacy data collected on healthy volunteers (GFT505-1084 studies) demonstrate clear beneficial effects of GFT505 on plasma lipids and inflammation markers. The anticipated large efficacy/safety ratio accelerates...

Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition

Tue, 02 Dec 2008 14:50:10 GMT

MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Dec 2, 2008 - Gemin X Pharmaceuticals announced today that preclinical data from the company's targeted cancer therapy, obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor, will be presented in three...

Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology

Tue, 02 Dec 2008 14:35:50 GMT

EDISON, N.J., December 02, 2008 /PRNewswire/ -- Daiichi Sankyo, Inc. , today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American Society of...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

Tue, 02 Dec 2008 14:25:05 GMT

LA JOLLA, Calif., December 02, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with...

Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

Tue, 02 Dec 2008 14:21:00 GMT

Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., December 02, 2008 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...

Inovio: final melanoma trial results confirm systemic effect and safety

Tue, 02 Dec 2008 13:50:23 GMT

First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Plasmid IL-12 and Electroporation Combination Against Metastatic Melanoma...

XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease

Tue, 02 Dec 2008 13:45:03 GMT

XP19986 Monotherapy Generally Well Tolerated and Effective in Reducing Heartburn in GERD Subjects Previously Treated with Proton Pump Inhibitors SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec 2, 2008 - XenoPort, Inc. (Nasdaq:XNPT) announced today...

First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical's Electroporation Technology Shows Safety and Durable Systemic Clinical Response

Tue, 02 Dec 2008 13:40:55 GMT

Plasmid IL-12 and Electroporation Combination Against Metastatic Melanoma Achieves Systemic Response in Untreated Lesions Without Reaching Dose-Limiting Toxicity Pioneering Results Published in Journal of Clinical Oncology SAN DIEGO--(BUSINESS...

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference

Tue, 02 Dec 2008 13:40:17 GMT

MONROVIA, Calif.--(BUSINESS WIRE)--Dec 2, 2008 - Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485 respectively, for...